Skip to main content
Beilstein Journal of Organic Chemistry logoLink to Beilstein Journal of Organic Chemistry
. 2006 Aug 25;2:16. doi: 10.1186/1860-5397-2-16

Multiple hydride reduction pathways in isoflavonoids

Auli K Salakka 1, Tuija H Jokela 1, Kristiina Wähälä 1,✉
PMCID: PMC1630637  PMID: 16934147

Abstract

Background

Isoflavonoids are of interest owing to their appearance in metabolic pathways of isoflavones, and their estrogenic and other physiological properties, making them promising lead compounds for drug design.

Results

The reduction of isoflavones by various hydride reagents occurs by a 1,4-pathway in contrast to ordinary β-alkoxy-α,β-unsaturated ketones. Isoflavan-4-ones, cis- and trans-isoflavan-4-ols, α-methyldeoxybenzoins or 1,2-diphenylprop-2-en-1-ols are obtained depending on the hydride reagent, mostly in good yields. The stereoselective reduction of isoflavan-4-ones is also discussed.

Conclusion

The work described in this paper shows that most structural types of reduced isoflavonoids are now reliably available in satisfactory or good yields by hydride reductions to be used as authentic reference compounds in analytical and biological studies.

Background

The reduction of isoflavones 1 has been actively studied during the last twenty years, owing to the range of interesting biological effects [1–3] – estrogenic activity, promise in cancer, osteoporosis, and coronary heart disease prevention – shown by the isoflavones themselves and their reduced metabolites. There are some reports [4–8] of total syntheses of reduced isoflavonoid structures from commercially available starting materials but overall yields in these multistep procedures tend to be low, and free hydroxy groups are not compatible. Another strategy involves the hydrogenation of isoflavones using a palladium or platinum catalyst but mixtures of reduction products are often formed [9–10]. Certain hydride reagents have been tested, as discussed below, for the reduction of simple or protected isoflavones but many of the early results are contradictory or rely on indeterminate product characterization.

The reduction of simple (nonflavonoid) β-alkoxy-α,β-unsaturated ketones by hydride reagents (NaBH4, LiAlH4, DIBAH) occurs normally by 1,2-attack, this being a key step in the well known "carbonyl transposition" of 1,3-diketone enol ethers into enones (R3O-CR=CR1-COR2 → R-CO-CR1=CHR2). [11–15] Prior to our work there were no reports on the reduction of isoflavones containing free hydroxy groups which nevertheless are common, usually at one or several of the C-5, C-7 and C-4' sites, in the naturally occurring isoflavonoids. It is to be expected that the presence of the phenolic hydroxyls, or the derived phenolate anions, will alter the reactivity pattern of the parent isoflavone system, besides perhaps decreasing the overall reactivity due to solubility reasons. For example, any tendency of hydride attack at the C-2 will be opposed by electron feeding from the 4'-OH group while an OH group at C-5 or C-7 will discourage attack at C-2 and C-4. Thus there was ample room for the development of reliable methods for the synthesis of hydroxy-substituted isoflavone metabolites, and for clarification of the course of reduction of isoflavones with various hydride reducing agents. We present here experimental details of our own results in this field together with a thorough survey of the literature. The discussion is based on the types of reduced isoflavonoid structures formed (Figure 1), i.e., isoflavanones 2, cis-isoflavan-4-ols 3, trans-isoflavan-4-ols 4, the ring opened α-methyldeoxybenzoins 5 and 1,2-diaryl-2-propen-1-ols 6, and isoflavenes 7 and 8 (hydride reductions do not lead to isoflavans 9, which however are obtained by catalytic hydrogenation [10,16,20]). Incidentally, it is appropriate to point out that flavones do not undergo similar reductive metabolism in mammals as described above for isoflavones. We will nevertheless present at a later date certain findings on the hydride reduction pathways in flavones.

Figure 1.

Figure 1

Isoflavonoid subclasses.

Results and Discussion

Isoflavanones (2)

Isoflavanones result from the 1,4-reduction of isoflavones. The resonance contributor 10 will encourage this mode of attack. DIBAH, normally a preferential 1,2-reducer, reacts with methoxy-, benzyloxy-, MOMO- and MEMO-substituted isoflavones to give the isoflavanones in 40–93% yield [16,21–23] (Table 1). Our own work has shown that even unprotected hydroxy-substituted isoflavones are reduced by a large excess of DIBAH in 50–70% yield (Table 1). The simple borohydride reagents reduce isoflavones to the isoflavanols (see below) but the Selectrides® give 60–88% yields of isoflavanones in the absence of hydroxy substituents according to our results (Table 1). There is no significant difference between the K- and L-Selectride®. In the literature, there is an isolated report of the reduction of a MOM substituted isoflavone by L-Selectride® in 40% yield (Table 2) [16]. Methoxy substituted isoflavones have also been reduced by sodium hydrogen telluride to give isoflavan-4-ones in 61–71% yields [24].

Table 1.

Reduction of isoflavones to isoflavanones.a

graphic file with name Beilstein_J_Org_Chem-02-16-i001.jpg
a all R groups = H
b R7 = OMe, other R groups = H
c R4' = R7 = OMe, other R groups = H
d R7 = OH, other R groups = H
e R4' = OMe, R7 = OH, other R groups = H
f R4' = OMe, R5 = R7 = OH, other R groups = H

R2' R3' R4' R5' R6' R5 R6 R7 R8 reductant, eqs yield %

DIBb, 4 72
SELc, 4 96
OH DIB, 10 68
SEL, 8 0
OMe DIB, 2.5 90d,e
DIB, 6 57
SEL, 4 84
Me OMe OMe DIB, 2.5 75e
OMe OMe OMe DIB, 2.5 89e
OMe OMe OMe NaHTe, 2 68f
OH OH DIB, 25 70
SEL, 8 0
OMe OH DIB, 25 60
OMe OMe DIB, 2.5 87e
DIB, 7 54
NaHTe, 2 61f
SEL, 4 82
OMOM OMOM DIB, 4.7 93g
OH OH OH DIB, 25 50
SEL, 9 0
OMe OH OH DIB, 25 57
OMe OMe OMe OMe NaHTe, 2 71f
OMOM OMOM OMOM DIB, 4.7 87g,h
SEL, 2 40g
OMe OMe OBn OBn DIB, 2.5 40i
OBn OMe OMe OMe DIB, 2.5 56e
OBn OBn OMe OMe OMe DIB, 1.9 52j
OBn OBn OBn OMe OMe DIB, 1.9 57j
OBn OBn OMe OMe OMe OBn DIB, 1.9 67j
OBn OMe OMe OMe OBn DIB, 1.9 61j
OBn OBn OBn OMe OMe OBn DIB, 1.9 58j

a Only substituents other than H are shown in the Table. Items without a reference are results reported here for the first time. b DIB = di-isobutylaluminiumhydride. c SEL = K- or L-Selectride®. d 2-Methyl-7-methoxyisoflavone reacted similarly in 63% yield.[21] e Ref. 21. f Ref. 24. g Ref. 16. h The corresponding tris(methoxyethoxymethoxy)flavone reacted similarly. i Ref. 23. j Ref. 22.

Table 2.

Reduction of isoflavones to isoflavan-4-olsa

graphic file with name Beilstein_J_Org_Chem-02-16-i002.jpg

SM R2 R2' R4' R6 R7 R8 reductant, eqs, solvent yield 3+4 % 3:4 ratio Yld 6 %

1a NaBH4,2.5,EtOH 86 70:30 12
LiBH4,2.5,THF 56 80:20 40
NaBH4,2.5,MeOH 57b 3 only
NaBH4,2,EtOH 75c,d
NaBH4,2,diglyme 88d,e
NaBH4,3.5,PdCl2,aq. THF 85 82:18
NaBH4,H3BO3,2.5, EtOH 98 71:29
NaBH4,CeCl3,1.0, DMSO 99 3 only
NaBH4,AlCl3,excess., digl. 81d
Zn(BH4)2,4,Et2O 69 62:38 19
LiEt3BH,4,THF 50 70:30
B2H6, excess,THF 76c,d
1b OMe NaBH4,2.5,EtOH 90 70:30 9
NaBH4,H3BO3,3.1, EtOH 80f 3 only
NaBH4,H3BO3,2.5, EtOH 97 70:30
NaBH4,CeCl3,1.5, DMSO 88 3 only 12
LiBH4,10,THF 54 70:30 37
LiEt3BH,4,THF 55 65:35
1c OMe OMe NaBH4,2.5,MeOH 37b 3 only
NaBH4,2.5,EtOH 88 70:30 10
NaBH4,CeCl3,2.5, DMSO 86 3 only 10
NaBH4,H3BO3,2.5, EtOH 96 70:30
LiBH4,10,THF 70 77:23 10
Zn(BH4)2,2,Et2O 74 62:38
LiEt3BH,4,THF 36 78:22
1 OMOM OMOM OMOM NaBH4,15.9,EtOH, THF
LiBH4,10,THF
87g
82g
65:35
57:43
1 Me Br OMe NaBH4,4.2,EtOH 25e,h
1 Me Br OBn NaBH4,4.2,EtOH 22e,h
1 Me OMe Br NaBH4,4.2,EtOH 20e,h
1 Me Br OMe Br NaBH4,4.2,EtOH 20e,h

a Only substituents other than H are shown. According to our results, OH substituted isoflavones are not reduced, nor are such reactions reported in the literature. Items without a reference are results reported here for the first time. b Ref. 25. c Product was given as 2-isoflaven-4-ol. d Ref. 28. e Product ratio not given. f Ref. 26. g Ref. 16. h Ref. 27.

Isoflavanols (3, 4)

Full reduction at the heterocyclic ring of isoflavones by LiBH4 or NaBH4 leads to isoflavanols in 20–91% yield (Table 2), [16,25–28]except with hydroxy substituted substrates which do not react at all. Apparently the first step involves a 1,4-addition to give the isoflavanone enolate which picks up a proton from the solvent and is reduced further to the saturated alcohol. There are no reports of the intermediacy of the alternative 1,2-reduction products, the allylic alcohols 11 which in fact appear very incompletely known in the chemical literature (see below). Similarly, the reduction of isoflavanones 2 by LiBH4, NaBH4, L-Selectride® or Li(t-BuO)3AlH gives mixtures of cis-3 and trans-isoflavan-4-ols 4 (Table 3). [16,29,34] Isoflavanones are reduced by electrophilic hydrides (borane-tetrahydrofuran, bis-tert-butylthioethane borane) diastereoselectively to cis-isoflavan-4-ols, but a large excess of the reducing agent is usually needed [29].

Table 3.

Reduction of isoflavanones to isoflavan-4-olsa

graphic file with name Beilstein_J_Org_Chem-02-16-i003.jpg

SM R2' R3' R4' R7 reductant, eqs, solvent yield 3+4 % 3:4 ratio

2a NaBH4, ng.,EtOH
NaBH4,2,MeOH,THF
Li(t-BuO)3AlH,10,THF
B2H6,80,THF
99b
99c
99c
98c
70:30
42:58
34:66
3 only
2b OMe NaBH4,2,MeOH,THF
NaBH4,1.2,EtOH
Li(t-BuO)3AlH,10,THF
L-Selectride, ng
B2H6,80,THF
BTEDg,0.7,THF
99c
67d
99c
99c
99c
98c
44:56
67:33
33:67
37:63
3 only
3 only
2 OH OH LiBH4,6.9,THF 94e 70:30
2 OTBDMS OTBDMS LiBH4,2,THF 96f 70:30
2c OMe OMe NaBH4,2,THF,MeOH
NaBH4,1.2,EtOH
Li(t-BuO)3AlH,10,THF
B2H6,80,THF
99c
50d
99c
97c
43:57
3 only
34:66
3 only
BTEDg,0.7,THF 97c 3 only
2 OMe OMe OMe NaBH4,2,THF,MeOH 99c 36:64
Li(t-BuO)3AlH,10,THF 99c 32:68
B2H6,80,THF 98c 3 only
BTEDg,0.7,THF 98c 3 only
2 OMOM OMOM OMOM LiBH4,10,THF 73h 55:45
LiAlH4,17,THF 78h 45:55
NaBH4,15.9,THF,MeOH 91h 70:30

a Only substituents other than H are shown. ng not given b Ref. 31. c Ref. 29. d Ref. 30. e Ref. 32. f Ref. 33. g bis-t-butylthioethane diborane. h Ref. 16.

Although it was realized by the early workers that diastereomeric mixtures of isoflavanols would presumably be formed, there were no reliable methods to determine their structures. In some papers, the products are summarily assigned the cis [25–26] or trans [35–38] structures. However, rigorous NMR analysis has recently made it possible to establish cis- and trans-structures for the isoflavanol products and to study their conformational equilibria [32,34]. Borohydride reductions generally give a small preference for the cis products as suggested by Cram's rule [39]. We are not aware of any examples in the literature of single enantiomers of isoflavanone or isoflavanol metabolites, nor have such compounds been reported as hydride reduction products of isoflavones. In view of the significant biological properties of the reduced metabolites it will be interesting to examine the behaviour of the pure enantiomers.

2-Isoflaven-4-ols (11)

There are very few reports of this class of compounds, either from reductive processes or otherwise. In 1965, the reduction of the parent isoflavone by NaBH4 in EtOH or diborane in THF was claimed [28] to furnish 2-isoflaven-4-ol in 75–76% yield, but unfortunately the characterization of this product relied on elemental analysis only. More recently, Japanese workers [40] reported that the reduction of 12 (Figure 2) by NaBH4 in the presence of PdCl2 in THF-H2O gave a 1:1 mixture of the ketone 13a and the diol 13b (Figure 2). A 1H NMR spectrum was given for the latter isoflavenol but there appear to be certain discrepancies, notably in the δ value (8.69) reported for the H-8 which is some 2 δ units in excess of what would be expected for such a vinyl ether proton. Thus more work is required to fully confirm the nature of this class of reduction products. In the event, in our studies the reduction of isoflavone 1a by NaBH4 in the presence of PdCl2 in THF-H2O gave a 82:18 mixture of cis- and trans-isoflavan-4-ol 3a, 4a while no 2-isoflaven-4-ols were observed. The absence of such 1,2-reduction products, or structures conceivably derivable thereof such as 2- or 3-isoflavenes (7, 8), even in the CeCl3-complexed NaBH4 reductions, must reflect the good stabilization obtainable via resonance heteroring stabilization (10) in the isoflavones. As already mentioned, this is in contrast to the behaviour of simple non-flavonoid β-alkoxy-α,β-unsaturated ketones which prefer 1,2-attack by hydride.

Figure 2.

Figure 2

2-Isoflaven-4-ols and 1-(2-hydroxyphenyl)-2-phenyl-2-propen-1-one

Isoflavenes (7, 8) and isoflavans (9)

In the early work, [41] there is a mention of 7,4'-dimethoxy-2-methyl-3-isoflavene being obtained in 15% yield from the reduction of the corresponding isoflavone by LiAlH4 in Et2O-benzene but there is no structural data on the product other than elemental analysis, itself quite accurate. Similarly 2',4'-dimethoxy-3',6,7-trihydroxyisoflav-3-ene was reported from the reduction of 2',4'-dimethoxy-3',6,7-trihydroxyisoflavan-4-one with LiAlH4 in low yield [42]. More recent work by us [43] and others [16,44] would indicate that the normal course of LiAlH4 reduction of isoflavones leads to deoxybenzoins and propenols (see below and Table 4).

Table 4.

Reduction of isoflavones to α-methyldeoxybenzoins and 1,2-diaryl-2-propen-1-olsa

graphic file with name Beilstein_J_Org_Chem-02-16-i004.jpg
a all R groups = H
b R7 = Me, other R groups = H
c R4 = R7 = Me, other R groups = H

R2' R4' R5 R7 reductant, eqs, solvent yield (%)
of 5 of 6

LiAlH4, 2.5,THF 27b 48
Li(t-BuO)3AlH, 5,THF 74 6
Red-Al, 2.5,THF 12 50
LiBH4, 10, THF 9 68
OMe LiAlH4, 2.5,THF 29b 50
LiAlH4, 1, THF 62c -
Li(t-BuO)3AlH,10,THF 88 12
LiBH4, 10, THF 7 37
OMe OMe LiAlH4,3.3,THF 27b 70
Li(t-BuO)3AlH,10,THF 88 12
LiBH4, 10, THF 5 10
OH LiAlH4,3.3,THF 60b -
Li(t-BuO)3AlH,8,THF - -
OH OH LiAlH4,5.5,THF 42b -
Li(t-BuO)3AlH,10,THF - -
OMe OH LiAlH4,3.3,THF 42b -
OH OH OH LiAlH4,5.5,THF 66b -
OMe OH OH LiAlH4,4.3,THF 70b -
OH OMe LiAlH4,3.3,THF 17b 34
OMOM OMOM OMOM LiAlH4,7.9,THF 6d -

a Only substituents other than H are shown in the Table. Items without a reference are results reported here for the first time. b Ref. 43. c Ref. 44. d Ref. 16.

Published syntheses of 2- and 3-isoflavenes involve the reduction of 3-arylcoumarins, [45–47] the corresponding aldehyde hemiacetals, [7] isoflavylium salts [48–50] or of isoflavones by the Clemmensen reaction [51]. Low-yielding non-reductive routes to 2- and/or 3-isoflavenes have also been reported [52–53]. 2-Isoflavenes 7 however remain mostly poorly characterized, and some of the NMR spectral details reported [7,51–52] appear inconsistent with the 2-isoflavenoid structure. As far as the NMR spectra of 2-isoflavenes are concerned, a recent study clears this issue by 2D NMR work on a natural 2-isoflavene, [54] establishing that the H-2 and H-4 protons appear at δ 6.87 and 3.61, respectively, much as expected by correlation data shift calculations. Isoflavans (9) have not been prepared by hydride reductions, but by catalytic hydrogenation of isoflavones [10,16–20].

Deoxybenzoins (5) and propenols (6)

Isoflavanones undergo a facile retro-Michael-type ring opening [21,55] under basic conditions to give the propenone intermediate 14 (Figure 2), sometimes considered [56] to be an independent isoflavone metabolite but presumably just an artefact in reality. As regards the synthesis of isoflavanones by DIBAH reduction of isoflavones (see above), we found that unless the workup is done with cold methanolic HCl, some amount of the propenone 14 will be formed and reduced further to the deoxybenzoin 5. If on the other hand the deoxybenzoins are the actual synthetic targets, the reducing agent of choice is LiAlH4 in THF. This works very well for isoflavones bearing a hydroxy group at C-7 such as genistein, but in isoflavones lacking a 7-OH group another reaction pathway competes leading to the propenols 6 [43] as byproducts (see below). We have discussed a possible mechanism to explain these hydroxyl-dependent divergent pathways [43].

To summarize, all hydride addition reactions with isoflavones appear to involve an initial 1,4-addition to give the isoflavanone enolate. In a hydroxylic solvent, or even on workup under basic conditions, the ketone is generated, and reduced further to the saturated alcohol (NaBH4). In a nonprotic solvent, the β-aryloxyenolate will undergo a retro-Michael addition, giving the phenolate anion of the ring opened 2-propen-1-one which may undergo a 1,2- or 1,4-addition of hydride (LiAlH4, LiBH4). If the O-metal bond in the initial enolate is very tight, the ring opening does not occur and allows the isolation of the isoflavanone (DIBAH, Selectrides®). The presence and number of hydroxy or alkoxy substituents in the substrates does not have a major effect in these reductions except in the case of NaBH4 reduction which fails completely presumably due to solubility reasons, and the LiAlH4 reduction where the outcome depends on the presence or absence of an OH group at C-7. Based on our and previous results by other workers, the reducing agents of choice for the synthesis of reduced isoflavonoids are as follows:

isoflavanones (2) from non-hydroxylated isoflavones DIBAH or Selectrides®

isoflavanones (2) from hydroxylated isoflavones DIBAH

cis-isoflavanols (3) from non-hydroxylated isoflavones NaBH4/CeCl3

cis-isoflavanols (3) from hydroxylated isoflavones no good methods

cis-isoflavanols (3) from non-hydroxylated isoflavanones B2H6 or BTED

trans-isoflavanols (4) from isoflavones no good methods

trans-isoflavanols (4) from isoflavanones Li(t-BuO)3AlH

2-isoflaven-4-ols (11) from isoflavones uncertain

isoflavenes (7, 8) from isoflavones Clemmensen

isoflavans (9) from isoflavones H2, Pd/BaSO4

α-methyldeoxybenzoins (5) from non-hydroxylated isoflavones Li(t-BuO)3AlH

α-methyldeoxybenzoins (5) from hydroxylated isoflavones LiAlH4

1,2-diaryl-2-propen-1-ols (6) from non-hydroxylated isoflavones LiBH4 or LiAlH4

Conclusion

Dietary isoflavonoids in vegetables, beans, peas and other legumes are possible cancer preventing agents, particularly in hormone based cancers such as breast and prostate cancer. [57–59] Epidemiological studies have shown that they decrease the risk of colon cancer, osteoporosis, and coronary heart disease. [1–3] Significantly, health claims of soy foods, rich in isoflavonoids, have recently received FDA authorization [60].

The dietary isoflavonoids are mainly metabolized in man via reductive pathways, leading to the reduced structural types discussed above (Figure 3). These compounds are often more estrogenic than the starting isoflavones. Research interest in many fields including medicine, nutrition and biosynthesis and metabolism thus converge on the reduced isoflavonoids. The work described in this paper shows that most structural types of reduced isoflavonoids are now reliably available in satisfactory or good yields by hydride reductions. Although not discussed here, it is clear that D atoms may be introduced in the same way which is very useful in the quantitation of the naturally occurring compounds by GC-MS selected ion monitoring techniques [61].

Figure 3.

Figure 3

Dietary isoflavones and their metabolites in humans.

e R4’=OMe, R7= OH, other R groups = H

f R4’= OMe, R5=R7= OH, other R groups = H

g R4’= R5=R7= OH, other R groups = H

h R4’=R7= OH, other R groups = H

i R4’=R7= OH, R6=OCH3, other R groups = H

j R4’= R6=R7= OH, other R groups = H

k R3’= R7= OH, other R groups = H

l R3’=R4’=R7= OH, other R groups = H

Supporting Information

File 1

Experimental details and characterisation data.

Acknowledgments

This work was partially funded within the Finnish Academy project no 178253. Funding to AKS and THJ from the Foundation of Emil Aaltonen and from the Jenny and Antti Wihuri Foundation to KW are gratefully acknowledged. We thank Dr Jorma Matikainen for running the mass spectra and Ms. Jenni Maria Petäjistö for the skilful laboratory assistance.

Contributor Information

Auli K Salakka, Email: auli.salakka@kemira.com.

Tuija H Jokela, Email: tuija.h.jokela@helsinki.fi.

Kristiina Wähälä, Email: kristiina.wahala@helsinki.fi.

References

  • 1.Cornwell T, Cohick W, Raskin I. Phytochemistry. 2004;65:995–1016. doi: 10.1016/j.phytochem.2004.03.005. [DOI] [PubMed] [Google Scholar]
  • 2.Cos P, De Bruyne T, Apers S, Van den Berghe D, Pieters L, Vlietinck A J. Planta Med. 2003;69:589–599. doi: 10.1055/s-2003-41122. [DOI] [PubMed] [Google Scholar]
  • 3.Duncan A M, Phipps W R, Kurzer M S. Best Pract Res Clin Endocrinol Metab. 2003;17:253–271. doi: 10.1016/S1521-690X(02)00103-3. [DOI] [PubMed] [Google Scholar]
  • 4.Bezuidenhoudt B C B, Brandt E V, Roux D G. J Chem Soc, Perkin Trans 1. 1981:263–269. doi: 10.1039/p19810000263. [DOI] [Google Scholar]
  • 5.Jain A C, Mehta A. J Chem Soc, Perkin Trans 1. 1986:215–220. doi: 10.1039/p19860000215. [DOI] [Google Scholar]
  • 6.Shih T L, Wyvratt M J, Mrozik H. J Org Chem. 1987;52:2029–2033. doi: 10.1021/jo00386a024. [DOI] [Google Scholar]
  • 7.Liepa A J. Aust J Chem. 1984;37:2545–2558. [Google Scholar]
  • 8.Gopal D, Rajagopalan K. Indian J Chem. 1987;26B:401. [Google Scholar]
  • 9.Szabó V, Antal E. Tetrahedron Lett. 1973;19:1659–1662. doi: 10.1016/S0040-4039(01)96021-6. [DOI] [Google Scholar]
  • 10.Szabó V, Antal E. Acta Chim Acad Sci Hung. 1976;90:381–393. [Google Scholar]
  • 11.Jensen N P, Brown R D, Schmitt S M, Windholz T B, Patchett A A. J Org Chem. 1972;37:1639–1647. doi: 10.1021/jo00975a040. [DOI] [PubMed] [Google Scholar]
  • 12.Gannon W F, House H O. Org Synth. 1960;40:14–15. [Google Scholar]
  • 13.Danishefsky S, Kerwin J F, Kobayashi S. J Am Chem Soc. 1982;104:358–360. doi: 10.1021/ja00365a095. [DOI] [Google Scholar]
  • 14.Kende A S, Benechie M, Curran D P, Fludzinski P, Swenson W, Clardy J. Tetrahedron Lett. 1979;20:4513–4516. doi: 10.1016/S0040-4039(01)86636-3. [DOI] [Google Scholar]
  • 15.Denmark S E, Habermas K L, Hite G A. Helv Chim Acta. 1988;71:168–194. doi: 10.1002/hlca.19880710120. [DOI] [Google Scholar]
  • 16.Süsse M, Johne S, Hesse M. Helv Chim Acta. 1992;75:457–470. doi: 10.1002/hlca.19920750205. [DOI] [Google Scholar]
  • 17.Adlercreutz H, Musey P I, Fotsis T, Bannwart C, Wähälä K, Mäkelä T, Brunow G, Hase T. Clin Chim Acta. 1986;158:147–154. doi: 10.1016/0009-8981(86)90230-5. [DOI] [PubMed] [Google Scholar]
  • 18.Luk K-C, Stern L, Weigele M. J Nat Prod. 1983;46:852–861. doi: 10.1021/np50030a005. [DOI] [PubMed] [Google Scholar]
  • 19.Antus S, Gottsegen Á, Kolonits P, Nógrádi M. Liebigs Ann Chem. 1986:2179–2181. [Google Scholar]
  • 20.Wähälä K, Valo T, Brunow G, Hase T. Finn Chem Lett. 1989;16:79–83. [Google Scholar]
  • 21.Antus S, Gottsegen Á, Nógrádi M. Synthesis. 1981:574–576. doi: 10.1055/s-1981-29535. [DOI] [Google Scholar]
  • 22.Antus S, Gottsegen Á, Kolonits P, Nagy Z, Nógrádi M, Vermes B. J Chem Soc, Perkin Trans 1. 1982:1389–1394. doi: 10.1039/p19820001389. [DOI] [Google Scholar]
  • 23.Májor Á, Nógrádi M, Vermes B, Kajtár-Peredy M. Liebigs Ann Chem. 1988:555–558. [Google Scholar]
  • 24.Jain A C, Kumar A, Sharma N K. Indian J Chem. 1991;30B:290–291. [Google Scholar]
  • 25.Yamaguchi S, Ito S, Nakamura A, Inoue N. Bull Chem Soc Jpn. 1965;38:2187–2189. doi: 10.1246/bcsj.38.2187. [DOI] [Google Scholar]
  • 26.Anjaneylu A S R, Sri Krishna C, Ramachandra Row L. Tetrahedron. 1965;21:2677–2681. doi: 10.1016/S0040-4020(01)93923-7. [DOI] [Google Scholar]
  • 27.Badran M M, El-Saba H M. Egypt J Pharm Sci. 1991;32:149–155. [Google Scholar]
  • 28.Thakar G P, Janaki N, Subba Rao B C. Indian J Chem. 1965:74–77. [Google Scholar]
  • 29.Chidiak H, Kirkiacharian S. Arm Khim Zh. 1996;49:94–104. [Google Scholar]
  • 30.Inoue N. Bull Chem Soc Jpn. 1964;37:601–606. doi: 10.1246/bcsj.37.601. [DOI] [Google Scholar]
  • 31.Szabó V, Borbély J, Antal E. Acta Chim Acad Sci Hung. 1979;102:51–57. [Google Scholar]
  • 32.Wähälä K, Koskimies J K, Mesilaakso M, Salakka A K, Leino T K, Adlercreutz H. J Org Chem. 1997;62:7690–7693. doi: 10.1021/jo970892u. [DOI] [Google Scholar]
  • 33.Wähälä K, Salakka A, Adlercreutz H. Proc Soc Exp Biol Med. 1998;217:293–299. doi: 10.3181/00379727-217-44235. [DOI] [PubMed] [Google Scholar]
  • 34.Pihlaja K, Tähtinen P, Klika K D, Jokela T, Salakka A, Wähälä K. J Org Chem. 2003;68:6864–6869. doi: 10.1021/jo0301200. [DOI] [PubMed] [Google Scholar]
  • 35.Anjaneyulu A S R, Rao M G, Row L R, Krishna C S. Tetrahedron Lett. 1966;7:3199–3202. doi: 10.1016/S0040-4039(01)99937-X. [DOI] [Google Scholar]
  • 36.Anjaneyulu A S R, Krishna C S, Row L R. Bull Natl Inst Sci India. 1965:118. [Google Scholar]
  • 37.Inoue N, Yamaguchi S, Fujiwara S. Bull Chem Soc Jpn. 1964;37:588–600. doi: 10.1246/bcsj.37.588. [DOI] [Google Scholar]
  • 38.Yamaguchi S, Ito S, Suzuki I, Inoue N. Bull Chem Soc Jpn. 1968;41:2073. doi: 10.1246/bcsj.41.2073. [DOI] [Google Scholar]
  • 39.Gomis M, Kirkiacharian B S. Tetrahedron. 1990;46:1849–1858. doi: 10.1016/S0040-4020(01)89754-4. [DOI] [Google Scholar]
  • 40.Tsukayama M, Kawamura Y, Tamaki H, Kubo T, Horie T. Bull Chem Soc Jpn. 1989;62:826–832. doi: 10.1246/bcsj.62.826. [DOI] [Google Scholar]
  • 41.Bradbury R B, White D E. J Chem Soc. 1953:871–876. doi: 10.1039/jr9530000871. [DOI] [Google Scholar]
  • 42.Shoukry M M, Darwish N A, Morsi M A. Gazz Chim Ital. 1982;112:289–291. [Google Scholar]
  • 43.Salakka A, Wähälä K. J Chem Soc, Perkin Trans 1. 1999:2601–2604. doi: 10.1039/a904946k. [DOI] [Google Scholar]
  • 44.Vermes B, Antus S, Gottsegen Á, Nógrádi M. Liebigs Ann Chem. 1983:2034–2037. [Google Scholar]
  • 45.Bulut M. Chim Acta Turc. 1991;19:17–26. [Google Scholar]
  • 46.Grese T A, Pennington L D. Tetrahedron Lett. 1995;36:8913–8916. doi: 10.1016/0040-4039(95)01916-6. [DOI] [Google Scholar]
  • 47.Verma P, Singh S, Dikshit D K, Ray S. Synthesis. 1988:68–70. doi: 10.1055/s-1988-27468. [DOI] [Google Scholar]
  • 48.Liepa A J. Aust J Chem. 1981;34:2647–2655. [Google Scholar]
  • 49.Bouvier P, Adrieux J, Cunha H, Molho D. Bull Soc Chim Fr. 1977:1187–1194. [Google Scholar]
  • 50.Deschamps-Vallet C, Ilotse J-B, Meyer-Dayan M. Tetrahedron Lett. 1983;24:3993–3996. doi: 10.1016/S0040-4039(00)88245-3. [DOI] [Google Scholar]
  • 51.Dudley K H, Miller H W, Corley R C, Wall M E. J Org Chem. 1967;32:2317–2321. doi: 10.1021/jo01282a049. [DOI] [PubMed] [Google Scholar]
  • 52.Diaz P, Gendre F, Stella L, Charpentier B. Tetrahedron. 1998;54:4579–4590. doi: 10.1016/S0040-4020(98)00169-0. [DOI] [Google Scholar]
  • 53.Baranton F, Fontaine G, Maitte P. Bull Soc Chim Fr. 1968:4203–4208. [Google Scholar]
  • 54.Miyase T, Sano M, Yoshino K, Nonaka K. Phytochemistry. 1999;52:311–319. doi: 10.1016/S0031-9422(99)00194-6. [DOI] [PubMed] [Google Scholar]
  • 55.Szabó S, Antal E. Magy Kem Foly. 1976;10:474–477. Chem. Abstr.1977,86, 55118a. [Google Scholar]
  • 56.Kelly G E, Nelson C, Waring M A, Joannou G E, Reeder A Y. Clin Chim Acta. 1993;223:9–22. doi: 10.1016/0009-8981(93)90058-C. [DOI] [PubMed] [Google Scholar]
  • 57.Pollard M, Wolter W. Prostate. 2000;45:101–105. doi: 10.1002/1097-0045(20001001)45:2<101::AID-PROS3>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  • 58.Lamartiniere C A. Am J Clin Nutr. 2000;71:1705S–1707S. doi: 10.1093/ajcn/71.6.1705S. [DOI] [PubMed] [Google Scholar]
  • 59.Wiseman H. Expert Opin Invest Drugs. 2000;9:1829–1840. doi: 10.1517/13543784.9.8.1829. [DOI] [PubMed] [Google Scholar]
  • 60.Federal register 64FR57699, U.S. Food and Drug Administration, Oct 26, 1999
  • 61.Adlercreutz H, Fotsis T, Lampe J, Wähälä K, Mäkelä T, Brunow G, Hase T. Scand J Clin Lab Invest. 1993;215:5S–18S. doi: 10.3109/00365519309090693. [DOI] [PubMed] [Google Scholar]
  • 62.Gensler W J, Johnson F, Sloan A D B. J Am Chem Soc. 1960;82:6074–6081. doi: 10.1021/ja01508a026. [DOI] [Google Scholar]
  • 63.Fisher G B, Harrison J, Fuller J C, Goralski C T, Singaram B. Tetrahedron Lett. 1992;33:4533–4536. doi: 10.1016/S0040-4039(00)61305-9. [DOI] [Google Scholar]
  • 64.Olah G A, Wang Q, Prakash G K S. Synlett. 1992:647–650. doi: 10.1055/s-1992-21443. [DOI] [Google Scholar]
  • 65.Ibrahim A-R, Abul-Hajj Y J. J Nat Prod. 1990;53:644–656. doi: 10.1021/np50072a011. [DOI] [PubMed] [Google Scholar]
  • 66.Osawa K, Yasuda H, Maruyama T, Morita H, Takeya K, Itokawa H. Chem Pharm Bull. 1992;40:2970–2974. doi: 10.1248/cpb.40.2970. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

File 1

Experimental details and characterisation data.


Articles from Beilstein Journal of Organic Chemistry are provided here courtesy of Beilstein-Institut

RESOURCES